Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
34 participants
OBSERVATIONAL
2018-04-01
2019-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Gastric cancer treatment includes the total or subtotal resection of the stomach which can influence the gastric acid production. However, the influence by alterations in gastric milieu after this treatment on the composition of the intestinal microbiome is not well studied.
Therefore, the intestinal microbiome of patients after total or subtotal gastrectomy and its influence on intestinal inflammation and gut permeability will be studied.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of the Use of Probiotics on the Intestinal Microbiota of Patients With Gastric Cancer
NCT06250075
The Gut Microbiome As an Indicator of Readiness for Head & Neck Cancer Surgery
NCT05061316
Effect of Gastrectomy on Gut Microbiome and Cognitive Function
NCT06186089
Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery
NCT06349590
"The Impact of Immunonutrition on Gut Microbiota-related Aspects in Colorectal Cancer and Gastric Cancer Patients"
NCT04980950
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test group
Patients who underwent total or subtotal gastrectomy for the treatment of gastric cancer
No interventions assigned to this group
Control group 1
Patients who underwent endoscopic mucosal resection/submucosal dissection for the treatment of gastric cancer
No interventions assigned to this group
Control group 2
In-house relatives of Test group and Control group 1 participants
No interventions assigned to this group
Control group 3
Patients with long-term history of proton pump inhibitor usage
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* history of radical removal of gastric cancer (Test group and Control group 1) or PPI (Control group 3)
* informed consent
Exclusion Criteria
* gastric stump cancer
* usage of antibiotics, pro- pre or synbiotics, H2-blocker 1 month prior to inclusion
* PPI use (except for Control group 3) 1 month prior to inclusion
* history of radical removal of gastric cancer (Control group 2-3)
* history of gastrointestinal tract resections (other than gastric)
* recurrence of gastric cancer
* current non-gastric malignancies
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Graz
OTHER
National Cancer Institute (NCI)
NIH
Vilnius University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rimantas Bausys
Medical Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Institute
Vilnius, , Lithuania
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Horvath A, Bausys A, Sabaliauskaite R, Stratilatovas E, Jarmalaite S, Schuetz B, Stiegler P, Bausys R, Stadlbauer V, Strupas K. Distal Gastrectomy with Billroth II Reconstruction is Associated with Oralization of Gut Microbiome and Intestinal Inflammation: A Proof-of-Concept Study. Ann Surg Oncol. 2021 Feb;28(2):1198-1208. doi: 10.1245/s10434-020-08678-1. Epub 2020 Jun 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DiGMA_2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.